scholarly journals Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer

2021 ◽  
Vol 22 (5) ◽  
pp. 2757
Author(s):  
Braden Miller ◽  
Hunter Chalfant ◽  
Alexandra Thomas ◽  
Elizabeth Wellberg ◽  
Christina Henson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Imaging Techniques ◽  
Growth Factor Receptor ◽  
Breast Cancer Diagnosis ◽  
Screening Mammography ◽  
Imaging Modalities ◽  
Conventional Imaging ◽  
Obese Women ◽  
Detection Rates ◽  
Therapeutic Decision Making

Obesity, diabetes, and inflammation increase the risk of breast cancer, the most common malignancy in women. One of the mainstays of breast cancer treatment and improving outcomes is early detection through imaging-based screening. There may be a role for individualized imaging strategies for patients with certain co-morbidities. Herein, we review the literature regarding the accuracy of conventional imaging modalities in obese and diabetic women, the potential role of anti-inflammatory agents to improve detection, and the novel molecular imaging techniques that may have a role for breast cancer screening in these patients. We demonstrate that with conventional imaging modalities, increased sensitivity often comes with a loss of specificity, resulting in unnecessary biopsies and overtreatment. Obese women have body size limitations that impair image quality, and diabetes increases the risk for dense breast tis-sue. Increased density is known to obscure the diagnosis of cancer on routine screening mammography. Novel molecu-lar imaging agents with targets such as estrogen receptor, human epidermal growth factor receptor 2 (HER2), pyrimi-dine analogues, and ligand-targeted receptor probes, among others, have potential to reduce false positive results. They can also improve detection rates with increased resolution and inform therapeutic decision making. These emerg-ing imaging techniques promise to improve breast cancer diagnosis in obese patients with diabetes who have dense breasts, but more work is needed to validate their clinical application.

Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes

2021 ◽  
Author(s):  
Marissa B. Lawson ◽  
Christoph I. Lee ◽  
Daniel S. Hippe ◽  
Shasank Chennupati ◽  
Catherine R. Fedorenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Late Stage ◽  
Breast Cancer Diagnosis ◽  
Screening Mammography ◽  
Socioeconomic Deprivation ◽  
Tumor Characteristics ◽  
Stage Disease ◽  
Increased Risk ◽  
Late Stage Disease

Background: The purpose of this study was to determine factors associated with receipt of screening mammography by insured women before breast cancer diagnosis, and subsequent outcomes. Patients and Methods: Using claims data from commercial and federal payers linked to a regional SEER registry, we identified women diagnosed with breast cancer from 2007 to 2017 and determined receipt of screening mammography within 1 year before diagnosis. We obtained patient and tumor characteristics from the SEER registry and assigned each woman a socioeconomic deprivation score based on residential address. Multivariable logistic regression models were used to evaluate associations of patient and tumor characteristics with late-stage disease and nonreceipt of mammography. We used multivariable Cox proportional hazards models to identify predictors of subsequent mortality. Results: Among 7,047 women, 69% (n=4,853) received screening mammography before breast cancer diagnosis. Compared with women who received mammography, those with no mammography had a higher proportion of late-stage disease (34% vs 10%) and higher 5-year mortality (18% vs 6%). In multivariable modeling, late-stage disease was most associated with nonreceipt of mammography (odds ratio [OR], 4.35; 95% CI, 3.80–4.98). The Cox model indicated that nonreceipt of mammography predicted increased risk of mortality (hazard ratio [HR], 2.00; 95% CI, 1.64–2.43), independent of late-stage disease at diagnosis (HR, 5.00; 95% CI, 4.10–6.10), Charlson comorbidity index score ≥1 (HR, 2.75; 95% CI, 2.26–3.34), and negative estrogen receptor/progesterone receptor status (HR, 2.09; 95% CI, 1.67–2.61). Nonreceipt of mammography was associated with younger age (40–49 vs 50–59 years; OR, 1.69; 95% CI, 1.45–1.96) and increased socioeconomic deprivation (OR, 1.05 per decile increase; 95% CI, 1.03–1.07). Conclusions: In a cohort of insured women diagnosed with breast cancer, nonreceipt of screening mammography was significantly associated with late-stage disease and mortality, suggesting that interventions to further increase uptake of screening mammography may improve breast cancer outcomes.

Breast cancer diagnosis: Imaging techniques and biochemical markers

2018 ◽  
Vol 233 (7) ◽  
pp. 5200-5213 ◽  
Author(s):  
Seyed Hamed Jafari ◽  
Zahra Saadatpour ◽  
Arash Salmaninejad ◽  
Fatemeh Momeni ◽  
Mojgan Mokhtari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Biochemical Markers ◽  
Imaging Techniques ◽  
Breast Cancer Diagnosis

scholarly journals CytoPAN—Portable cellular analyses for rapid point-of-care cancer diagnosis

2020 ◽  
Vol 12 (555) ◽  
pp. eaaz9746
Author(s):  
Jouha Min ◽  
Lip Ket Chin ◽  
Juhyun Oh ◽  
Christian Landeros ◽  
Claudio Vinegoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Point Of Care ◽  
Growth Factor Receptor ◽  
Image Cytometry ◽  
Breast Cancer Diagnosis ◽  
Needle Aspiration ◽  
Current Standard ◽  
Diagnose Breast Cancer ◽  
Palpable Mass

Rapid, automated, point-of-care cellular diagnosis of cancer remains difficult in remote settings due to lack of specialists and medical infrastructure. To address the need for same-day diagnosis, we developed an automated image cytometry system (CytoPAN) that allows rapid breast cancer diagnosis of scant cellular specimens obtained by fine needle aspiration (FNA) of palpable mass lesions. The system is devoid of moving parts for stable operations, harnesses optimized antibody kits for multiplexed analysis, and offers a user-friendly interface with automated analysis for rapid diagnoses. Through extensive optimization and validation using cell lines and mouse models, we established breast cancer diagnosis and receptor subtyping in 1 hour using as few as 50 harvested cells. In a prospective patient cohort study (n = 68), we showed that the diagnostic accuracy was 100% for cancer detection and the receptor subtyping accuracy was 96% for human epidermal growth factor receptor 2 and 93% for hormonal receptors (ER/PR), two key biomarkers associated with breast cancer. A combination of FNA and CytoPAN offers faster, less invasive cancer diagnoses than the current standard (core biopsy and histopathology). This approach should enable the ability to more rapidly diagnose breast cancer in global and remote settings.

scholarly journals Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study

2020 ◽  
Vol 59 (12) ◽  
pp. 1528-1537
Author(s):  
Ida Skarping ◽  
Daniel Förnvik ◽  
Uffe Heide-Jørgensen ◽  
Lisa Rydén ◽  
Sophia Zackrisson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Treatment Response ◽  
Tumor Size ◽  
Breast Cancer Treatment ◽  
Imaging Modalities ◽  
Conventional Imaging ◽  
Size Evaluation

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

2010 ◽  
Vol 36 (4) ◽  
pp. 387-392 ◽  
Author(s):  
T.S. Aukema ◽  
E.J.Th. Rutgers ◽  
W.V. Vogel ◽  
H.J. Teertstra ◽  
H.S. Oldenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Fdg Pet ◽  
Imaging Techniques ◽  
Cancer Recurrence ◽  
Breast Cancer Recurrence ◽  
Conventional Imaging ◽  
Pet Ct ◽  
Fdg Pet Ct

Mammography use in women age 80 and older with breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9039-9039
Author(s):  
S. H. Giordano ◽  
B. Badgwell ◽  
Z. Duan ◽  
I. Bedrosian ◽  
G. Hortobagyi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Health Care Providers ◽  
Tumor Size ◽  
Age Groups ◽  
Breast Cancer Diagnosis ◽  
Screening Mammography ◽  
Stage Ii ◽  
Care Providers ◽  
Mammography Use

9039 Background: The guidelines for screening mammography use in patients age 80 years and older are not clear. The purpose of this study was to determine the effect of mammography use on stage and tumor size at breast cancer diagnosis. Methods: The study is a retrospective cohort using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. We evaluated 14,976 women aged 80 and older diagnosed with breast cancer between 1996–2002. Patients were divided into three cohorts based on screening mammography use in the 60 months prior to diagnosis: nonusers, non-regular users (1–2 mammograms), and regular users (3+). The effects of screening on tumor stage (0-I vs. II-IV) and size were determined by logistic regression and multivariate analysis of variance. Results: Regular mammography use for the age groups 80–84, 85–89, and >= 90 was 29%, 19%, and 9%, respectively. Among regular users of mammography, 26% presented with stage II or greater cancer while 64% of non-users presented with stage II or greater disease. On multivariate analysis, non-users were 4.7 (95% CI 4.26–5.14) times more likely to present with high-stage cancer. Non-users, non-regular users, and regular users had an adjusted mean tumor size of 5.08 (4.44–5.72), 3.26 (2.57–3.95), and 2.77 (2.02–3.51), respectively. Conclusions: Regular screening mammography among women aged 80 years and older is associated with earlier stage at presentation and smaller tumor size compared to mammography nonusers. Health care providers should consider discussing potential benefits of screening mammography with their older patients particularly for those without significant comorbidity. No significant financial relationships to disclose.

scholarly journals The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Hadar Goldvaser ◽  
Shulamith Rizel ◽  
Daniel Hendler ◽  
Victoria Neiman ◽  
Daniel Shepshelovich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metabolic Disorders ◽  
Growth Factor Receptor ◽  
Recurrence Score ◽  
Retrospective Chart Review ◽  
Breast Cancer Diagnosis ◽  
Study Cohort ◽  
Er Positive ◽  
Study Population ◽  
Statin Usage

Purpose. To evaluate the associations between metformin, insulin, statins, and levothyroxine and breast cancer characteristics and outcome.Methods. Retrospective chart review of patients treated in our institute for early estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative breast cancer, whose tumors were sent to Oncotype DX (ODX) analysis. Patients were grouped according to medications usage during the time of breast cancer diagnosis. Each group was compared to the rest of the study population.Results. The study cohort included 671 patients. Sixty (9.1%) patients were treated with metformin, 9 (1.4%) with insulin, 208 (31.7%) with statins, and 62 (9.4%) with levothyroxine. Patients treated with metformin had more intense ER stain (p=0.032) and a lower ODX recurrence score (RS) (p=0.035). Diagnosis of diabetes mellitus was also associated with lower ODX RS (p=0.014). Insulin usage was associated with a higher rate of angiolymphatic invasion (p=0.041), but lower Ki67% (p=0.017). Levothyroxine usage was associated with different histological subtype distribution (p=0.02). Extended levothyroxine usage was associated with lower ODX RS (p=0.005). Statin usage had no impact on tumor characteristics. Outcome was comparable in the studied subgroups.Conclusions. Common medications for metabolic disorders might be associated with breast cancer characteristics.

Original Paper: Contribution of clinical breast examination to mammography screening in the early detection of breast cancer

2003 ◽  
Vol 10 (1) ◽  
pp. 16-21 ◽  
Author(s):  
C Bancej ◽  
K Decker ◽  
A Chiarelli ◽  
M Harrison ◽  
D Turner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Breast Cancer Mortality ◽  
Clinical Breast Examination ◽  
Screening Mammography ◽  
Detection Rates ◽  
Breast Examination ◽  
Mode Of Detection ◽  
Clinical Breast ◽  
Interim Measures

Objectives: As the benefit of clinical breast examination (CBE) over that of screening mammography alone in reducing breast cancer mortality is uncertain, it is informative to monitor its contribution to interim measures of effectiveness of a screening programme. Here, the contribution of CBE to screening mammography in the early detection of breast cancer was evaluated. Setting: Four Canadian organised breast cancer screening programmes. Methods: Women aged 50-69 receiving dual screening (CBE and mammography) (n=300,303) between 1996 and 1998 were followed up between screen and diagnosis. Outcomes assessed by mode of detection (CBE alone, mammography alone, or both CBE and mammography) included referral rate, positive predictive value, pathological features of tumours (size, nodal status, morphology), and cancer detection rates overall and for small cancers (≤10 mm or node-negative). Heterogeneity in findings across programmes was also assessed. Results: On first versus subsequent screen, CBE alone resulted in 28.5-36.7% of referrals, and 4.6-5.9% of cancers compared with 52.6-60.1% of referrals and 60.0-64.3% of cancers for mammography alone. Among cancers detected by CBE, 83.6-88.6% were also detected by mammography, whereas for mammographically detected cancers only 31.7-37.2% were also detected by CBE. On average, CBE increased the rate of detection of small invasive cancers by 2-6% over rates if mammography was the sole detection method. Without CBE, programmes would be missing three cancers for every 10,000 screens and 3-10 small invasive cancers in every 100,000 screens. Conclusions: Inclusion of CBE in an organised programme contributes minimally to early detection.

Annual Mammography Screening: Is it Necessary?

2012 ◽  
Vol 78 (1) ◽  
pp. 104-106
Author(s):  
Veronica Hegar ◽  
Kristin Oliveira ◽  
Bharat Kakarala ◽  
Alicia Mangram ◽  
Ernest Dunn
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Task Force ◽  
Treatment Options ◽  
Retrospective Chart Review ◽  
Breast Cancer Diagnosis ◽  
Screening Mammography ◽  
Screening Mammograms ◽  
System 1 ◽  
Preventative Services

Recent recommendations from the U.S. Preventative Services Task Force suggest that screening mammography for women should be biennial starting at age 50 years and continue to age 74 years. With these recommendations in mind, we proposed a study to evaluate women at our institution in whom breast cancer is diagnosed within 1 year of a previously benign mammogram. A retrospective chart review was performed over a 4-year period. Only patients who had both diagnostic mammograms and previous mammograms performed at our institution and a pathologic diagnosis of breast cancer were included. Benign mammograms were defined as either Breast Imaging Reporting And Data System 1 or 2. Analysis of the time elapse between benign mammogram and subsequent mammogram indicative of the diagnosis of breast cancer was performed. A total of 205 patients were included. The average age was 64 years. From our results, 48 patients, 23 per cent of the total, had a documented benign mammogram at 12 months or less before a breast cancer diagnosis. One hundred forty-three (70%) patients had a benign mammogram at 18 months or less prior. This study raises concern that 2 years between screening mammograms may delay diagnosis and possible treatment options for many women.

Sign in / Sign up

Export Citation Format

Share Document